Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study Scarisbrick, J., Horwitz, S. M., Prince, H., Whittaker, S., Duvic, M., Kim, Y. H., Quaglino, P., Zinzani, P., Bechter, O., Eradat, H., Pinter-Brown, L., Akilov, O., Geskin, L., Sanches, J., Ortiz-Romero, P., Lisano, J., Brown, L., Bunn, V., Little, M., Dummer, R. ELSEVIER SCI LTD. 2019: S31
View details for Web of Science ID 000508019000083